Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cells for COVID-19 Pneumonia
NCT04280224Phase 1Completed
- Sponsor
- Xinxiang Medical University
- Start
- Feb 2020
- Primary completion
- Dec 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of NK cell therapy (Anhui Provincial Hospital) in COVID-19 pneumonia, sponsored by Xinxiang Medical University. Primary endpoints: Duration of fever at 28 days and Respiratory frequency at 28 days. Started Feb 2020; status: completed.
02
Drugs
NK cell therapy (Anhui Provincial Hospital)
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04280224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04280224.